Skip to Content

Novartis Gains US Approval For New MS Drug

From Associated Press (September 22, 2010)

GENEVA -- Swiss drug maker Novartis says it has gained approval from U.S. regulators for a new multiple sclerosis treatment.

Novartis says the U.S. Food and Drug Administration has approved Gilenya for oral use with relapsing forms of multiple sclerosis

The Basel-based company says a two-year placebo-controlled study showed the drug significantly reduced the risk of disability progression.

Novartis said Wednesday that it is pursuing regulatory approval in Europe and the rest of the world.

Shares in the company were down 0.8 percent at 56.00 Swiss francs ($56.54) on the Zurich exchange.


Posted: September 2010